Cheng-Jun Zhu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Cheng-Jun Zhu has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Rong-Rong He
State Key Laboratory of Mechanism and Quality of Chinese Medicine/School of Pharmacy/Faculty of Chinese Medicine, Faculty of Medicine, Macau University of Science and Technology, Macau 999078, China
2 shared publications - Wen-Jun Duan
Guangdong Engineering Research Center of Chinese Medicine & Disease Susceptibility, Jinan University, Guangzhou 510632, China
2 shared publications - Xiao-Min Lin
Institute for Intelligent Bioinnovation, Knowledge Transfer Center, City University of Macau, Macao Special Administrative Region, China
2 shared publications - Yunfeng Cao
Shanghai-MOST Key Laboratory of Health and Disease Genomics, NHC Key Lab of Reproduction Regulation, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Shanghai, China
2 shared publications - Chang-Yu Yan
School of Integrated Chinese and Western Medicine, Anhui University of Chinese Medicine, Hefei 230012, China
1 shared publication - Chang-Yu Yan
Guangdong Engineering Research Center of Chinese Medicine & Disease Susceptibility, Jinan University, Guangzhou 510632, China
1 shared publication
Latest Publications
- Open Access
- 3 July 2023
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 133 (13)
Midbrain dopamine oxidation links ubiquitination of glutathione peroxidase 4 to ferroptosis of dopaminergic neurons
- 3 July 2023
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 133 (13)
Open AccessMidbrain dopamine oxidation links ubiquitination of glutathione peroxidase 4 to ferroptosis of dopaminergic neurons
- Open Access
- 15 May 2023
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 133 (10)
Midbrain dopamine oxidation links ubiquitination of glutathione peroxidase 4 to ferroptosis of dopaminergic neurons
Parkinson’s disease (PD) is a neurodegenerative disorder characterized by the gradual loss of midbrain dopaminergic neurons in association with aggregation of α-synuclein. Oxidative damage has been widely implicated in this disease, though the mechanisms involved remain elusive. Here, we demonstrated that preferential accumulation of peroxidized phospholipids and loss of the antioxidant enzyme glutathione peroxidase 4 (GPX4) were responsible for vulnerability of midbrain dopaminergic neurons and progressive motor dysfunctions in a mouse model of PD. We also established a mechanism wherein iron-induced dopamine oxidation modified GPX4, thereby rendering it amenable to degradation via the ubiquitin-proteasome pathway. In conclusion, this study unraveled what we believe to be a novel pathway for dopaminergic neuron degeneration during PD pathogenesis, driven by dopamine-induced loss of antioxidant GPX4 activity.
- 15 May 2023
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 133 (10)
Open AccessMidbrain dopamine oxidation links ubiquitination of glutathione peroxidase 4 to ferroptosis of dopaminergic neurons
Parkinson’s disease (PD) is a neurodegenerative disorder characterized by the gradual loss of midbrain dopaminergic neurons in association with aggregation of α-synuclein. Oxidative damage has been widely implicated in this disease, though the mechanisms involved remain elusive. Here, we demonstrated that preferential accumulation of peroxidized phospholipids and loss of the antioxidant enzyme glutathione peroxidase 4 (GPX4) were responsible for vulnerability of midbrain dopaminergic neurons and progressive motor dysfunctions in a mouse model of PD. We also established a mechanism wherein iron-induced dopamine oxidation modified GPX4, thereby rendering it amenable to degradation via the ubiquitin-proteasome pathway. In conclusion, this study unraveled what we believe to be a novel pathway for dopaminergic neuron degeneration during PD pathogenesis, driven by dopamine-induced loss of antioxidant GPX4 activity.